FDA accepts UroGen's UGN-102 NDA for bladder cancer treatment

Retrieved on: 2024-10-16 17:02:36

Tags for this article:

Bladder cancer

Food and Drug Administration

New Drug Application

Nogapendekin alfa inbakicept

Click the tags to see associated articles and topics

FDA accepts UroGen's UGN-102 NDA for bladder cancer treatment. View article details on hiswai:

Summary

The article discusses UroGen Pharma's NDA acceptance by the FDA for UGN-102, a bladder cancer drug, highlighting its innovative hydrogel technology. This aligns with "business intelligence" in understanding pharmaceutical regulatory advancements and market insights.

Article found on: www.pharmaceutical-technology.com

View Original Article